Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BEI Medical Plans Year 2000 PMA Filing For Endometrial HydroThermAblator

This article was originally published in The Gray Sheet

Executive Summary

BEI Medical Systems is on target to complete Phase III studies of its Hydro ThermAblator system for thermal endometrial ablation in the first quarter.

You may also be interested in...

Gynecologists Likely To Have New Options For Treating Menorrhagia In 2001

BEI Medical Systems' Hydro ThermAblator (HTA) system for endometrial ablation will provide a new option for gynecologists in the treatment of menorrhagia when it becomes available, likely in early 2001.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts